Your browser doesn't support javascript.
loading
Clinical characteristics and risk factors of drug-induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis.
Koshikawa, Ken; Terada, Jiro; Abe, Mitsuhiro; Iwasawa, Shunichiro; Sakayori, Masashi; Yoshioka, Keiichiro; Hirasawa, Yasutaka; Kasai, Hajime; Kawasaki, Yohei; Tsushima, Kenji; Tatsumi, Koichiro.
Afiliación
  • Koshikawa K; Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Terada J; Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Abe M; Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Iwasawa S; Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Sakayori M; Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Yoshioka K; Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Hirasawa Y; Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Kasai H; Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Kawasaki Y; Biostatistics Section, Clinical Research Center, Chiba University Hospital, Chiba, Japan.
  • Tsushima K; Department of Pulmonary Medicine, International University of Health and Welfare, School of Medicine, Narita city, Chiba, Japan.
  • Tatsumi K; Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Thorac Cancer ; 11(6): 1495-1502, 2020 06.
Article en En | MEDLINE | ID: mdl-32237210
BACKGROUND: If anaplastic lymphoma kinase (ALK) gene rearrangement in lung cancer is identified, ALK-tyrosine kinase inhibitors (ALK-TKIs) can be an effective treatment. However, the details of drug-induced lung injury (DILI) caused by ALK-TKI, which can be a serious side effect of ALK-TKIs, remains unclear. This study aimed to investigate the clinical features and the onset risk factors of DILI by ALK-TKIs in clinical practice. METHODS: The clinical features of 56 consecutive patients who received crizotinib, alectinib, and/or ceritinib at our hospital from 2012 to 2018 were retrospectively examined. Among these, patients diagnosed with DILI due to ALK-TKIs were evaluated in terms of clinical features and parameters. Each clinical parameter before the administration of ALK-TKIs was compared between the DILI onset group and the non-onset group. RESULTS: A total of seven cases were diagnosed with DILI due to ALK-TKIs; no DILI-related deaths were observed. Chest computed tomography (CT) scan findings identified six patients with the organizing pneumonia (OP) pattern and one with the hypersensitivity pneumonia pattern. The onset of DILI was significantly different in patients age ≥ 64 years and with a creatinine clearance <80 mL/minute. CONCLUSIONS: Extra caution for DILI due to ALK-TKIs may be needed when recommending ALK-TKIs for patients over 64 years of age, or with decreased renal function. CT images of the majority of patients with DILI by ALK-TKIs show an OP pattern. KEY POINTS: Significant findings of the study: Extra caution is needed when recommending ALK-TKIs for patients over 64 years of age or those with decreased renal function. Computed tomography images of the majority of patients with DILI by ALK-TKIs show an OP pattern. WHAT THIS STUDY ADDS: The same or a different ALK-TKI may be considered as a treatment option after the onset of DILI, based on careful judgment.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Inhibidores de Proteínas Quinasas / Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos / Lesión Pulmonar / Quinasa de Linfoma Anaplásico / Neoplasias Pulmonares Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Thorac Cancer Año: 2020 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Singapur

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Inhibidores de Proteínas Quinasas / Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos / Lesión Pulmonar / Quinasa de Linfoma Anaplásico / Neoplasias Pulmonares Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Thorac Cancer Año: 2020 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Singapur